Supplementary Appendix 1

Systematic literature search

May 2024

Search criteria (synonyms drawn from each database as appropriate): health care professional or pharmacist + COPD + randomised controlled /clinical trial



Papers included in the review

1. Aiken LS, Butner J, Lockhart CA, Volk-Craft BE, Hamilton G, et al. (2006) Outcome evaluation of a randomized trial of the PhoenixCare intervention: program of case management and coordinated care for the seriously chronically ill. J Palliat Med 9: 111–126.
2. Egan E, Clavarino A, Burridge L, Teuwen M, White E (2002) A randomized control trial of nursing-based case management for patients with chronic obstructive pulmonary disease. Lippincott's case management 7: 170–179.
3. Torres-Robles A, Benrimoj SI, Gastelurrutia MA, et al. Effectiveness of a medication adherence management intervention in a community pharmacy setting: a cluster randomised controlled trial. BMJ Quality & Safety 2022;31:105-115.
4. Freeman, C.R., Scott, I.A., Hemming, K., Connelly, L.B., Kirkpatrick, C.M., Coombes, I., Whitty, J., Martin, J., Cottrell, N., Sturman, N., Russell, G.M., Williams, I., Nicholson, C., Kirsa, S. and Foot, H. (2021), Reducing Medical Admissions and Presentations Into Hospital through Optimising Medicines (REMAIN HOME): a stepped wedge, cluster randomised controlled trial. Med. J. Aust., 214: 212-217.
5. Xin C, Xia Z, Jiang C, Lin M, Li G. The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: a randomized controlled study. Patient Prefer Adherence. 2016;10:1197-1203.
6. Wei L, Yang X, Li J, Liu L, Luo H, Zheng Z. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. J Thoracic Dis. 2014;6(6):656–662.
7. Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 2014;77(5):756-766.
8. Khdour MR, Agus AM, Kidney JC, Smyth BM, Elnay JC, Crealey GE. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm. 2011;33(4):665–73.
9. Jarab AS, AlQudah SG, Khdour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm. 2012;34(1):53-62.
10. Abdulsalim S, Unnikrishnan MK, Manu MK, Alrasheedy AA, Godman B, Morisky DE. Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study. Res Social Adm Pharm. 2018;14(10):909-914.
11. Gourley GA, Portner TS, Gourley DR, Rigolosi EL, Holt JM, Solomon DK, et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998;38(5):586–97.
12. Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998;38(5):574–85.
13. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA. 2002;288(13):1594–602.
14. Wei L, Li J, Luo H, Wei Y, Yang X, Liu L. Effects of pharmacy service on disease analysis and quality of life of chronic obstructive pulmonary disease. China Med Herald. 2013;10(17):163–5.

15. Wei L, Li J, Luo H, Wei Y, Yang X, Liu L. Effects of pharmaceutical care on drug compliance of patients with chronic obstructive pulmonary disease in stable phase. China Pharm. 2013;24(14):1316–8.

16. Gallefoss F, Bakke PS, Rsgaard PK. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:812–7.

17. Gallefoss F. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ Couns. 2004;52(3):259–66.

18. Gorgas TMQ, Pa`ez VF, Camo´s RJ, Jolonch SP, Homs PE, Schoenenberger AJA, et al. [Integrated pharmaceutical care programme in patients with chronic diseases]. Farm Hosp (1130- 6343). 2012;36(4):229–39.

19. Li Z, Fang Z, Ge M, Yang R, Zhu Y. Effects of integrated pharmaceutical care on patients with chronic obstructive pulmonary disease in community. Chin J Gen Pract. 2010;8(12):1561–3.

20. Li Z, Fang Z, Ge M, Yang R, Zhu Y. Intervention effects of integrated pharmaceutical care for community chronic obstructive pulmonary disease patients. Chin Genl Pract. 2011;14(13):1496–500.

21. Suhaj A, Manu MK, Unnikrishnan MK, Vijayanarayana K, Mallikarjuna Rao C. Effectiveness of clinical pharmacist intervention on health-related quality of life in chronic obstructive pulmonary disorder patients - a randomized controlled study. J Clin Pharm Ther. 2016 Feb;41(1):78-83.

22. Davies L, Wilkinson M, Bonner S, Calverley PM, Angus RM. Hospital at home versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000;321(7271):1265-8.

23. Ricauda 2008 {published data only} Ricauda NA, Tibaldi V, Le B, Scarafiotti C, Marinello R, Zanocchi M, et al. Substitutive hospital at home versus inpatient care for elderly patients with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Journal of the American Geriatrics Society 2008;56:493-500.